Physician profile
Gregory Vanfossen
NPI 1346310067
$1,995.87
in general payments reported to CMS, 2019-2025
22 companies · $316 in 2025
The $316 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $354 · 2022: $452 · 2023: $720 · 2024: $155 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,190.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $598.53 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $264.52 | 2021-2025 | Belbuca, Xtampza |
| Scilex Pharmaceuticals INC. | $230.09 | 2021-2023 | Ztlido |
| Antares Pharma, INC. | $137.77 | 2022-2023 | Xyosted, Nocdurna, Tlando |
| Pfizer INC. | $113.32 | 2021-2025 | |
| Novo Nordisk INC | $104.88 | 2021-2025 | Wegovy |
| Boston Scientific Corporation | $86.91 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $71.02 | 2022-2023 | Emgality, Reyvow |
| Ibsa Pharma INC. | $60.99 | 2021-2023 | Tirosint, Licart |
| Medtronic, INC. | $56.26 | 2025 | Inceptiv |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.50 | 2023 | Relistor |
| Biodelivery Sciences International, INC. | $34.46 | 2021 | |
| Allergan, INC. | $31.54 | 2021 | |
| Lundbeck LLC | $22.16 | 2023 | Vyepti |
| Nevro Corp. | $20.98 | 2023 | Senza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Halozyme INC | $19.82 | 2023 | |
| Grt US Holding, INC. | $19.09 | 2022 | |
| Supernus Pharmaceuticals, INC. | $17.49 | 2021 | Xyosted, Tlando |
| Hikma Pharmaceuticals USA | $17.40 | 2021 | |
| Averitas Pharma INC. | $16.97 | 2023 | Qutenza |
| Mdd US Operations, LLC | $15.54 | 2022 | |
| Horizon Therapeutics Plc | $11.63 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Vanfossen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.